Huntington's disease: the current state of research with peripheral tissues
- PMID: 19460373
- DOI: 10.1016/j.expneurol.2009.05.012
Huntington's disease: the current state of research with peripheral tissues
Abstract
Huntington's disease (HD) is a genetically dominant condition caused by expanded CAG repeats. These repeats code for a glutamine tract in the HD gene product huntingtin (htt), which is a protein expressed in almost all tissues. Although most HD symptoms reflect preferential neuronal death in specific brain regions, even before the HD gene was identified numerous reports had described additional abnormalities in the peripheral tissues of HD patients, including weight loss, altered glucose homeostasis, and sub-cellular abnormalities in fibroblasts, lymphocytes and erythrocytes. Several years have elapsed since the HD mutation was discovered, and analyses of peripheral tissues from HD patients have helped to understand the molecular pathogenesis of the disease and revealed that the molecular mechanisms through which mutated htt leads to cell dysfunction are widely shared between central nervous system (CNS) and peripheral tissues. These studies show that in peripheral tissues, mutated htt causes accumulation of intracellular protein aggregates, impairment of energetic metabolism, transcriptional deregulation and hyperactivation of programmed cell-death mechanisms. Here, we review the current knowledge of peripheral tissue alterations in HD patients and in animal models of HD and focus on how this information can be used to identify potential therapeutic possibilities and biomarkers for disease progression.
Similar articles
-
Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.Rev Neurosci. 2011 Dec 2;23(1):13-28. doi: 10.1515/RNS.2011.060. Rev Neurosci. 2011. PMID: 22150069 Review.
-
Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.Acta Biochim Pol. 2004;51(2):415-30. Acta Biochim Pol. 2004. PMID: 15218539 Review.
-
Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1007-19. doi: 10.1111/j.1440-1681.2005.04313.x. Clin Exp Pharmacol Physiol. 2005. PMID: 16445565 Review.
-
Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.Brain Res. 2008 Jan 10;1188:61-8. doi: 10.1016/j.brainres.2007.06.059. Epub 2007 Jul 14. Brain Res. 2008. PMID: 18062944
-
A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.Ann Neurol. 2001 Sep;50(3):373-80. Ann Neurol. 2001. PMID: 11558794 Corrected and republished.
Cited by
-
Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression.EMBO Mol Med. 2024 Mar;16(3):523-546. doi: 10.1038/s44321-023-00020-y. Epub 2024 Feb 19. EMBO Mol Med. 2024. PMID: 38374466 Free PMC article.
-
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.Int J Mol Sci. 2023 Aug 21;24(16):13021. doi: 10.3390/ijms241613021. Int J Mol Sci. 2023. PMID: 37629202 Free PMC article. Review.
-
Innate immune activation and aberrant function in the R6/2 mouse model and Huntington's disease iPSC-derived microglia.Front Mol Neurosci. 2023 Jun 20;16:1191324. doi: 10.3389/fnmol.2023.1191324. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37415834 Free PMC article.
-
What the Gut Tells the Brain-Is There a Link between Microbiota and Huntington's Disease?Int J Mol Sci. 2023 Feb 24;24(5):4477. doi: 10.3390/ijms24054477. Int J Mol Sci. 2023. PMID: 36901907 Free PMC article. Review.
-
The updated development of blood-based biomarkers for Huntington's disease.J Neurol. 2023 May;270(5):2483-2503. doi: 10.1007/s00415-023-11572-x. Epub 2023 Jan 24. J Neurol. 2023. PMID: 36692635 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
